

PMR Public Report

Operation Number	BL-U0001	Chief of Operations Validation Date	05/05/22
Year- PMR Cycle	Second period Jan-Dec 2021	Division Chief Validation Date	05/05/22
Last Update	05/04/22	Country Representative Validation Date	05/07/22
PMR Validation Stage	Validated by Representative		

Basic Data

Operation Profile

Operation Name	Support to the Financing of the Purchase of COVID-19 Vaccine and its Implementation	Loan Number	5234/OC-BL
Executing Agency	MINISTRY OF HEALTH	Sector/Subsector	HEALTH-DISEASE PREVENTION & CONTROL
Team Leader	AGUILAR RIVERA, ANA MYLENA	Overall Stage	Disbursing (From eligibility until all the Operations are closed)
Operation Type	Guarantee	Country	Belize
Lending Instrument	Investment	Convergence related Operation(s)	
Borrower	BELIZE		


Environmental and Social Safeguards

Impacts Category	C	Was/Were the objective(s) of this operation reformulated?	NO
Safeguard Performance Rating		Date of approval	
Safeguard Performance Rating - Rationale			

Financial Data

	Total Cost and Source					Available Funds (US\$)			
Operations	Original IDB	Current IDB	Local Counterpart	Co-Financing / Country	Total Original Cost	Current IDB	Disb. Amount to Date	% Disbursed	Undisbursed Amount
BL-U0001	2,137,260	1,235,100	0	0	2,137,260	1,235,100	-	0.00%	1,235,100
Aggregated	2,137,260	1,235,100	0	0	2,137,260	1,235,100	-	0.00%	1,235,100

Expense Categories by Loan Contract (cumulative values)



Please note that inactive indicators and outputs are not displayed; totals in the actual cost table may not match the sum of the cost of the outputs displayed, due to the cost of inactive outputs.

RESULTS MATRIX

General Development Objectives

General Development Objectives Nbr. 1: Contribute to the reduction of the morbidity and mortality caused by COVID-19 and to mitigate indirect impacts of the pandemic.

Observation: Baseline as of 16th of December 2020. The SIR model estimates a reduction of deaths with vaccine of 78% (3,605) and a reduction of cases of 78% with vaccine (192,000)

Indicator		Unit of Measure	Baseline	Baseline Year	Expected Year of Achievement	EOP 2036	
1.0	Number of Deaths from Covid-19	Number	212	2020	2023	P	787
						A	-

Details

Means of Verification: Epi data /BHIS/ Statistical Institute of Belize

Observations:

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

Pro-Gender	No	Pro-Ethnicity	No	CRF indicator					
Indicator				Unit of Measure	Baseline	Baseline Year	Expected Year of Achievement	EOP 2036	
1.1	Confirmed cases of COVID-19			Number	9672	2020	2023	P	42,000
								A	-
Details									

Means of Verification: Epi data /BHIS/ Statistical Institute of Belize

Observations:

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

Pro-Gender	No	Pro-Ethnicity	No	CRF indicator			

RESULTS MATRIX											
Specific Development Objectives											
Specific Development Objectives Nbr. 1: Supporting initiatives to break the chain of transmission of the illness											
Observation:											
	Indicator		Unit of Measure	Baseline	Baseline Year		2021	2022	2023	2024	EOP 2036
1.0	Percentage of health personnel who have been vaccinated against COVID-19		Percentage	0	2020	P	100	100	-	-	100
						A	50.3	-	-	-	-
Details											
Means of Verification: BHIS or vaccination monitoring system											
Observations:											
Evaluation Methodology: -											
Pro-Gender	No	Pro-Ethnicity	No	CRF indicator							
	Indicator		Unit of Measure	Baseline	Baseline Year		2021	2022	2023	2024	EOP 2036
1.1	Percentage of people in vulnerable groups (elderly and chronic disease patients) who have been vaccinated against COVID-19		Percentage	0	2020	P	40	95	-	-	95
						A	81.9	-	-	-	-
Details											
Means of Verification: BHIS or vaccination monitoring system											
Observations:											
Evaluation Methodology: -											
Pro-Gender	No	Pro-Ethnicity	No	CRF indicator							
	Indicator		Unit of Measure	Baseline	Baseline Year		2021	2022	2023	2024	EOP 2036
1.2	COVID-19 vaccine distribution plan developed		Plan	0	2020	P	1	-	-	-	1
						A	1	-	-	-	-
Details											
Means of Verification: Plan approved by the MoHW											
Observations:											
Evaluation Methodology: -											
Pro-Gender	No	Pro-Ethnicity	No	CRF indicator							
	Indicator		Unit of Measure	Baseline	Baseline Year		2021	2022	2023	2024	EOP 2036
1.3	Number of beneficiaries		# of beneficiaries	0	2020	P	50,400	29,250	39,750	-	119,400
						A	50,400	-	-	-	-
Details											
Means of Verification: MOHW reports of BHIS											
Observations:											
Evaluation Methodology: -											
Pro-Gender	No	Pro-Ethnicity	No	CRF indicator	2.2 Beneficiaries receiving health services (#) (C)						

RESULTS MATRIX

OUTPUTS: ANNUAL PHYSICAL AND FINANCIAL PROGRESS

Component Nbr. 1 Component 1. Ensuring timely vaccine availability

				PHYSICAL PROGRESS		FINANCIAL PROGRESS	
	Output	Unit of Measure		2021	EOP 2036	2021	EOP 2036
1.01	Number of doses of COVID-19 vaccines procured	Number	P	100,800	238,800	-	-
			P (a)	100,800	238,800	-	-
			A	100,800	100,800	-	-
Total Cost							
	Total Cost		P	100,800	238,800		
			P (a)	100,800	238,800		
			A	100,800	100,800		

No information available for this section

RISKS AND PLANNED RESPONSES

Risk ID	Risk Status		Risk Taxonomy
1	Inactive		Political Environment
	Response Actions		
	1.0	Management Strategy	Status
		-	

IMPLEMENTATION STATUS AND LEARNING

No Information available for this Section